Home » Topics » Regulatory

Regulatory
RSS

Cholesterol-lowering statin approved in first markets

Dec. 11, 1996

OsmoCyte approved for marketing in U.S.

Dec. 9, 1996

Cytovene approved for new indication in U.S.

Dec. 6, 1996

Once-daily antihypertensive combination cleared for marketing in Canada

Dec. 3, 1996

First approval for Aricept

Nov. 27, 1996

Water-soluble fiber introduced in first market for high cholesterol

Nov. 27, 1996

Lilly claims 5-HT7 antagonist for GI indications

Nov. 26, 1996

HMG-CoA reductase inhibitors for preventing second heart attack

Nov. 26, 1996

Neuregulin polypeptides described for treating retinal disorders

Nov. 26, 1996

Lilly claims new indication for olanzapine

Nov. 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.